Comment
doi: 10.1016/S0140-6736(02)09348-0.
Who is fooling us?
- PMID: 12114069
- DOI: 10.1016/S0140-6736(02)09348-0
Item in Clipboard
Comment
Who is fooling us?
Lancet.
.
No abstract available
Comment in
-
Who is fooling us?Lancet. 2002 Sep 14;360(9336):873-4. doi: 10.1016/S0140-6736(02)09974-9. Lancet. 2002. PMID: 12243941 No abstract available.
Comment on
-
Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack.Lancet. 2001 Sep 29;358(9287):1033-41. doi: 10.1016/S0140-6736(01)06178-5. Lancet. 2001. PMID: 11589932 Clinical Trial.
-
Blood-pressure reduction and cardiovascular risk in HOPE study.Lancet. 2001 Dec 22-29;358(9299):2130-1. doi: 10.1016/S0140-6736(01)07186-0. Lancet. 2001. PMID: 11784631
Similar articles
-
Who is fooling us?Lancet. 2002 Sep 14;360(9336):873-4. doi: 10.1016/S0140-6736(02)09974-9. Lancet. 2002. PMID: 12243941 No abstract available.
-
Best bang for the buck?Curr Hypertens Rep. 2003 Feb;5(1):3-5. doi: 10.1007/s11906-003-0002-4. Curr Hypertens Rep. 2003. PMID: 12530929 No abstract available.
-
Choosing an angiotensin-receptor blocker: blood pressure lowering, cardiovascular protection or both?Future Cardiol. 2010 Jan;6(1):129-35. doi: 10.2217/fca.09.61. Future Cardiol. 2010. PMID: 20014992 Review.
-
Risk reduction for stroke and coronary events.Lancet. 2002 Apr 6;359(9313):1249; author reply 1250-1. doi: 10.1016/S0140-6736(02)08234-X. Lancet. 2002. PMID: 11955568 No abstract available.
-
Angiotensin blockade in type 2 diabetes: what the new evidence tells us about renal and cardiac complications.Can J Cardiol. 2002 May;18 Suppl A:3A-6A. Can J Cardiol. 2002. PMID: 12045787 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
